From OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders
March 4, 2021
Lung cancer is one of the most common causes of cancer mortality globally, resulting in nearly 25 percent of all cancer-related deaths. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer according to the American Cancer Society, accounting for about 84 percent of lung cancer cases.
OHC plays a major role in helping patients in our community win the battle against lung cancer by providing cutting-edge treatments and clinical trials. OHC is conducting a first-of-its-kind observational trial to improve testing and treatment protocols for NSCLC and is enrolling patients at our Blue Ash, Fairfield, Eastgate, Hamilton, and West locations. The study, MYLUNG Consortium, “A Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective Real-World Evidence Study,” brings together diverse organizations across the spectrum of drug development, therapy, and care to observe up to 12,000 NSCLC patients over a five-year period.
“There are more treatment options than ever before for patients with NSCLC. This important study will deepen our understanding of the disease, allowing us to identify the optimum molecular testing and treatment protocol, and advancing hope for future lung cancer patients,” said David M. Waterhouse, MD, MPH, medical oncologist, hematologist, co-director of the department of clinical research at OHC and principal investigator for OHC’s lung cancer clinical trials.
MYLUNG is poised to support meaningful progress and innovation in care delivery and potentially touch and improve thousands of lives.Comments (0)